Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Correction of hypokalemia,Prevention of hypokalemia in patients at risk,Intravenous source of calories (dextrose)
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Potassium has no true elimination half-life as it is homeostatically regulated; the terminal half-life of a potassium load is approximately 8-12 hours in healthy individuals, but this is highly variable and dependent on renal function, aldosterone status, and body stores. In anuric patients, potassium clearance is minimal, and dangerous accumulation can occur within hours.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium is not metabolized; excreted primarily by kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Primarily renal; >90% of potassium is excreted by the kidneys, with approximately 10% lost in feces. In steady state, urinary potassium excretion matches dietary intake (typically 40-120 m Eq/day). Dextrose is completely metabolized; unchanged dextrose excretion is negligible (<1% renal) in normoglycemic individuals.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Potassium: negligible (<2%) protein binding; it is present as free ions. Dextrose: not protein bound.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Potassium: Vd ~0.5 L/kg (total body water); essentially distributes throughout the entire body water. Over 98% of total body potassium is intracellular; the Vd for administered potassium is larger than that for extracellular markers due to rapid cellular uptake. Dextrose distributes into total body water (Vd ~0.6 L/kg).
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Intravenous: 100% bioavailability. Not administered by other routes for potassium repletion due to poor tolerability and absorption (e.g., oral bioavailability of potassium chloride is 80-90%, but GI irritation limits use).
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
GFR <30 m L/min: avoid use unless documented hypokalemia; maximum infusion rate 5 m Eq/h. GFR 30-50 m L/min: reduce rate to 5-10 m Eq/h. GFR >50 m L/min: standard dosing.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No dose adjustment required for Child-Pugh class A or B. Class C: use with caution, monitor potassium levels and infusion rate; reduce maximum rate to 5 m Eq/h.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
0.5-1 m Eq/kg/dose IV, infused at a rate not exceeding 0.5-1 m Eq/kg/h; maximum concentration 40 m Eq/L for peripheral infusion. Adjust based on serum potassium levels.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Reduce initial infusion rate to 5 m Eq/h; monitor renal function and serum potassium closely due to age-related decline in GFR; maximum concentration 40 m Eq/L.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Potassium chloride injections are concentrated and must be diluted before administration. Rapid infusion may cause fatal hyperkalemia.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Risk of hyperkalemia, especially in renal impairment,Monitor serum potassium and ECG during administration,Do not administer undiluted,Use with caution in patients with cardiac disease, metabolic acidosis, or hypovolemia,Extravasation risk may cause tissue necrosis
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Hyperchloremia,Conditions exacerbated by fluid overload
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
No specific food interactions. However, dietary potassium intake should be monitored when on high-dose potassium supplementation to avoid hyperkalemia. Avoid consuming large amounts of potassium-rich foods (e.g., bananas, oranges, tomatoes) without consulting a healthcare professional.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, maternal hyperkalemia or severe acidosis/fluid shifts may adversely affect fetal outcome. Trimester-specific risks not established.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium and dextrose are normal constituents of breast milk. Intravenous administration results in minimal changes to milk composition. M/P ratio not applicable. Considered compatible with breastfeeding.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustments required. However, pregnant women may have increased plasma volume and altered renal function; standard dosing based on electrolyte and fluid deficits. Monitor serum potassium and glucose closely to avoid hyperkalemia or hyperglycemia.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Potassium chloride in dextrose 5% is an intravenous solution for correction of hypokalemia and provision of maintenance fluids. Monitor serum potassium, renal function, and ECG during infusion. Maximum infusion rate: 10-20 m Eq/hour with continuous cardiac monitoring. Avoid in severe hyperkalemia, renal failure with oliguria, or conditions with potassium retention. Use central line if concentration >60 m Eq/L. Do not administer undiluted. Incompatible with amphotericin B, cefepime, and others.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
This solution is given intravenously to replace potassium and provide hydration.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the infusion or adjust the rate on your own.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking potassium supplements or certain blood pressure medications.,Inform your provider if you feel tingling, muscle weakness, irregular heartbeat, or confusion.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, mater. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.